Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cytokinetics

43.19
+0.20000.47%
Post-market: 43.190.00000.00%17:20 EDT
Volume:1.52M
Turnover:65.25M
Market Cap:5.11B
PE:-8.20
High:43.33
Open:42.83
Low:41.70
Close:42.99
Loading ...

Cytokinetics, Incorporated (CYTK): the Most Oversold Pharma Stock to Buy According to Analysts

Insider Monkey
·
24 Feb

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
20 Feb

20 stocks of companies expected to put up numbers to back investors' new 'growth mindset'

Dow Jones
·
18 Feb

Cytokinetics rumor highlighted in Betaville alert

TIPRANKS
·
15 Feb

Cytokinetics Shares up 1.5% After Morgan Stanley Raises to Overweight From Equal-Weight

THOMSON REUTERS
·
13 Feb

Morgan Stanley Upgrades Cytokinetics to Overweight From Equalweight, Trims Price Target to $67 From $70

MT Newswires Live
·
13 Feb

Cytokinetics Shares up 2.7% Premarket After Morgan Stanley Raises to Overweight From Equal-Weight

THOMSON REUTERS
·
13 Feb

Positive Outlook for Cytokinetics: Buy Rating Based on Aficamten’s Advantages and Upcoming Catalysts

TIPRANKS
·
13 Feb

Cytokinetics upgraded to Overweight from Equal Weight at Morgan Stanley

TIPRANKS
·
13 Feb

BRIEF-Cytokinetics Names Robert E. Landry To Board Of Directors

Reuters
·
11 Feb

Cytokinetics Names Robert E. Landry to Board of Directors

THOMSON REUTERS
·
11 Feb

Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Insmed (INSM) and IQVIA Holdings (IQV)

TIPRANKS
·
11 Feb

Why Cytokinetics, Incorporated (CYTK) Is Among the Best Healthcare Stocks To Buy According to Analysts

Insider Monkey
·
08 Feb

Cytokinetics Initiated at Buy by Citigroup

Dow Jones
·
08 Feb

Citigroup Initiates Cytokinetics at Buy With $86 Price Target

MT Newswires Live
·
07 Feb

Optimistic Buy Rating for Cytokinetics Driven by Aficamten’s Market Potential and Undervalued Shares

TIPRANKS
·
07 Feb